Lipid Therapeutics

Drug development inflammation


HBM contact: Dr Alexander Asam

Company status: private

Lipid Therapeutics GmbH is developing novel therapies for inflammatory diseases of the digestive system. The company's current focus is to develop LT-02, a delayed release of Phosphatidylcholine, for the treatment of Ulcerative colitis. LT-02 is currently in PhIII clinical development. 

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171